Clinical Trial Update: A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating YKST02 in participants with relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• YKST02

Snippet

Sponsor: Excyte Biopharma Ltd | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING